Insmed INSM
NASDAQ INSM
$126.29 -0.39 (-0.31%)
At close: Sep 4, 2026 · 4:00 PM EDT

Insmed (INSM) Other Non-Current Assets (2011 - 2026)

Insmed (INSM) posted Other Non-Current Assets of $104.4 million for Q2 2026, up 5.2% on a QoQ basis from $99.3 million in Q1 2026, and up 17.6% year-over-year from $88.8 million in Q2 2025.

Analysis

Insmed (INSM) Other Non-Current Assets (2011 - 2026) Analysis & Trends

Insmed has reported Other Non-Current Assets for 16 years, with the latest figure at $104.4 million in Q2 2026.

  • On a quarterly basis, Other Non-Current Assets rose 17.6% year-over-year to $104.4 million in Q2 2026; TTM through Jun 2026 was $104.4 million, a 17.6% increase from a year earlier, with the FY2025 full-year figure at $97.4 million, up 4.45% from the prior year.
  • Other Non-Current Assets was $104.4 million for Q2 2026 at Insmed, up from $99.3 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $104.4 million in Q2 2026, with the low at $57.2 million in Q1 2022.
  • Average Other Non-Current Assets over 5 years is $86.7 million, with a median of $90.7 million recorded in 2025.
  • The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets soared 49.25% in 2022, then decreased 6.21% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $76.1 million in 2022, then advanced by 26.9% to $96.6 million in 2023, then dropped by 3.47% to $93.2 million in 2024, then advanced by 4.45% to $97.4 million in 2025, then climbed by 7.26% to $104.4 million in 2026.
  • The last three Other Non-Current Assets figures came in at $104.4 million (Q2 2026), $99.3 million (Q1 2026), and $97.4 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 12.98 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 4.75 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 2.31 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 124.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 618.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 65.13 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 831.80 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 104.44 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 104.44 Mn
Mar 31, 2026 99.28 Mn
Dec 31, 2025 97.38 Mn
Sep 30, 2025 91.61 Mn
Jun 30, 2025 88.81 Mn
Mar 31, 2025 89.76 Mn
Dec 31, 2024 93.23 Mn
Sep 30, 2024 96.86 Mn
Jun 30, 2024 85.83 Mn
Mar 31, 2024 95.70 Mn
Dec 31, 2023 96.57 Mn
Sep 30, 2023 92.49 Mn
Jun 30, 2023 83.45 Mn
Mar 31, 2023 81.32 Mn
Dec 31, 2022 76.10 Mn
Sep 30, 2022 63.71 Mn
Jun 30, 2022 66.30 Mn
Mar 31, 2022 57.20 Mn
Dec 31, 2021 50.99 Mn
Sep 30, 2021 47.60 Mn